Article

New data show bimatoprost's capability to treat IOP

Westport, Ireland-According to a study published in Ophthalmology this month (bimatoprost) (Lumigan) alone is just as effective at lowering IOP as a fixed combination of latanoprost combined with timolol.

Westport, Ireland-According to a study published in Ophthalmology this month (bimatoprost) (Lumigan) alone is just as effective at lowering IOP as a fixed combination of latanoprost combined with timolol.

The randomized double-blind study compared the effects of bimatoprost and latanoprost combined with timolol on IOP over a 24-hour period.

It is outlined in the guidelines of the European Glaucoma Society that bimatoprost appears to be one of the effective, well-tolerated agents for the reduction of IOP in patients with primary open-angle glaucoma and ocular hypertension.

The patients that participated in the study either had glaucoma or ocular hypertension and were on a non-fixed combination of latanoprost and timolol for at least 3 months or on either latanoproast or timolol and not fully controlled prior to enrollment.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
© 2025 MJH Life Sciences

All rights reserved.